|
Volumn 2, Issue 5, 2006, Pages 215-221
|
Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC®) in a large-scale, open, randomized safety study in healthy French infants
|
Author keywords
Fever; Hepatitis B; Hexavalent; Human; Infant; Pentavalent; Pertussis; Toddler; Vaccine
|
Indexed keywords
DIPHTERIA WHOLE CELL PERTUSIS INACTIVATED POLIOVIRUS TETANUS HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE;
DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE;
DIPHTHERIA VACCINE;
HAEMOPHILUS INFLUENZAE TYPE B VACCINE;
PENTACOQ;
PERTUSSIS VACCINE;
RECOMBINANT HEPATITIS B VACCINE;
TETANUS TOXOID;
UNCLASSIFIED DRUG;
ANAPHYLAXIS;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CRYING;
DOSE RESPONSE;
DRUG SAFETY;
FEMALE;
FEVER;
FRANCE;
HUMAN;
HUMAN EXPERIMENT;
IMMUNIZATION;
INCIDENCE;
INFANT;
INJECTION SITE REACTION;
MALE;
MULTICENTER STUDY;
MUSCLE HYPOTONIA;
NORMAL HUMAN;
OPEN STUDY;
PERIPHERAL EDEMA;
PURPURA;
RANDOMIZED CONTROLLED TRIAL;
RASH;
SIDE EFFECT;
VACCINATION;
|
EID: 33751219590
PISSN: 15548600
EISSN: 15548619
Source Type: Journal
DOI: 10.4161/hv.2.5.3220 Document Type: Article |
Times cited : (6)
|
References (9)
|